drugset / Trial / NCT03385369

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

NCT03385369

Phase 1 Completed 32 enrolled MedImmune LLC
RandomizedParallel-groupTriple-blindBasic science

Summary

This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent

Timeline

Start
2018-01-05
Primary completion
2018-04-12
Completion
2018-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide 50 ug Subcutaneous
Subject Cotadutide Peptide 100 ug Subcutaneous
Subject Cotadutide Peptide 150 ug Subcutaneous

Indications

No indication recorded.